💡 Quick answer
The landmark clinical studies, treatment history and latest research for History of Hair-Loss Treatment — fact-checked and sourced.
Research & evidence
How treatment evolved
1959Norman Orentreich publishes his work establishing the principle of 'donor dominance' (transplanted occipital follicles retain their resistance to balding) in the Annals of the New York Academy of Sciences, the scientific foundation of modern hair transplantation.
1988FDA approves topical minoxidil 2% (Rogaine, Upjohn) for male pattern baldness on Aug 17, 1988 — the first drug approved for hair loss. Minoxidil was repurposed after oral Loniten (FDA-approved 1979 for hypertension) was observed to cause hypertrichosis.
1997FDA approves oral finasteride 1 mg (Propecia, Merck) on Dec 19, 1997 for male androgenetic alopecia — the first oral drug for hair loss and the first 5-alpha-reductase inhibitor for this indication (the 5 mg dose, Proscar, had been approved for benign prostatic hyperplasia in 1992).
1995Bernstein and Rassman publish 'Follicular Transplantation,' establishing the use of naturally occurring 1-4 hair follicular units as the basis for surgical hair restoration — the foundation of follicular unit transplantation (FUT), shifting from large 'plug' punch grafts toward natural-looking results as the standard of care (the explicit 'follicular unit transplantation' terminology was codified in their follow-up papers in 1998-1999).
2022FDA approves oral baricitinib (Olumiant, Eli Lilly/Incyte) in June 2022, a JAK1/JAK2 inhibitor — the first systemic therapy approved in the US for severe alopecia areata (an autoimmune, not androgenetic, form of hair loss).
Key clinical studies
Kaufman et al. (Finasteride Male Pattern Hair Loss Study Group), 19981998
Two pooled double-blind placebo-controlled RCTs; 1,553 men aged 18-41 with vertex androgenetic alopecia; 2-year (1,215 men continued into year two).
Finasteride 1 mg/day increased vertex hair count by 107 hairs at 1 year and 138 hairs at 2 years versus placebo (P<.001), measured in a 1-inch-diameter circular area of balding vertex scalp (not ~1 cm); placebo-treated men showed progressive loss. Pivotal trial supporting FDA approval of Propecia.
BRAVE-AA1 and BRAVE-AA2 (King et al.), 20222022
Two phase 3 double-blind RCTs, 1,200 adults total with severe alopecia areata (baseline SALT score >=50), 36-week primary endpoint
At week 36, 35-39% of patients on baricitinib 4 mg achieved a SALT score <=20 (>=80% scalp coverage) versus 3-6% on placebo; the trials supported the 2022 FDA approval of baricitinib for severe alopecia areata.
Adil & Godwin meta-analysis, 20172017
Systematic review and meta-analysis of 22 RCTs of androgenetic alopecia treatments in men and women
Pooled analysis found minoxidil, oral finasteride, and low-level laser therapy all significantly increased hair count versus placebo, supporting them as effective evidence-based options; effect sizes were modest and trial quality was variable.
J Am Acad Dermatol (JAAD)
Latest research: The dominant recent direction (2023-2026) is the rapid, largely off-label adoption of low-dose oral minoxidil (typically 0.5-5 mg/day) for androgenetic and other alopecias, with multicenter safety studies and a 2024 international modified-Delphi consensus statement formalizing prescribing despite the absence of FDA approval for this use. In parallel, oral JAK inhibitors (baricitinib, ritlecitinib, and deuruxolitinib) are expanding systemic options for alopecia areata, including new pediatric/adolescent trials.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Explore more
Self-check →Treatments →Transplant →Women →New →Hair Loss Causes →Hair-Loss Glossary →Hair-Loss Questions & Answers →Hair-Loss Ingredient Evidence Ratings →Hair Transplant Cost by City →Research →Browse all →
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child